Quick Answer
Arbutus Biopharma Corp reported Cash And Cash Equivalents At Carrying Value of $18.01 million for the year ending 2025.
- Arbutus Biopharma Corp showed a decrease of -50.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Arbutus Biopharma Corp's annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $38.73 million | Q2 2013: $35.84 million | Q3 2013: $35.84 million | Q1 2014: $134.36 million | Q2 2014: $85.27 million | Q3 2014: $78.18 million | Q1 2015: $232.28 million | Q2 2015: $207.21 million | Q3 2015: $181.09 million | Q1 2016: $144.77 million | Q2 2016: $42.97 million | Q3 2016: $26.63 million | Q1 2017: $29.85 million | Q2 2017: $24.21 million | Q3 2017: $15.23 million | Q1 2018: $12.46 million | Q2 2018: $10.19 million | Q3 2018: $21.93 million | Q1 2019: $83.97 million | Q2 2019: $78.87 million | Q3 2019: $90.08 million | Q1 2020: $26.42 million | Q2 2020: $45.90 million | Q3 2020: $96.92 million | Q1 2021: $79.42 million | Q2 2021: $30.95 million | Q3 2021: $77.88 million | Q1 2022: $81.33 million | Q2 2022: $47.32 million | Q3 2022: $24.00 million | Q1 2023: $40.57 million | Q2 2023: $27.20 million | Q3 2023: $17.53 million | Q1 2024: $43.10 million | Q2 2024: $62.79 million | Q3 2024: $31.85 million | Q1 2025: $37.08 million | Q2 2025: $37.41 million | Q3 2025: $22.41 million.
- Over the full 18 years of available data (2008 to 2025), Arbutus Biopharma Corp's Cash And Cash Equivalents At Carrying Value has declined by 31.3%.
- Historical annual values: Fiscal year 2025: $18.01 million | Fiscal year 2024: $36.33 million | Fiscal year 2023: $26.29 million | Fiscal year 2022: $30.78 million | Fiscal year 2021: $109.28 million | Fiscal year 2020: $52.25 million | Fiscal year 2019: $31.80 million | Fiscal year 2018: $36.94 million | Fiscal year 2017: $54.29 million | Fiscal year 2016: $23.41 million | Fiscal year 2015: $166.78 million | Fiscal year 2014: $72.19 million | Fiscal year 2013: $68.72 million | Fiscal year 2012: $47.02 million | Fiscal year 2011: $9.03 million | Fiscal year 2010: $12.41 million | Fiscal year 2009: $24.40 million | Fiscal year 2008: $26.22 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: